EUDA Health Holdings Limited announced on December 16, 2024, that it has entered into preliminary discussions with Guangdong Cell Biotech Co. Ltd. to form a joint venture. Guangdong Cell Biotech is recognized as a prominent player in stem cell therapies and regenerative medicine.
The potential collaboration aims to leverage EUDA’s digital healthcare ecosystem to deliver cutting-edge regenerative therapies developed by Guangdong Cell Biotech to a broader audience in Southeast Asia. Guangdong Cell Biotech currently operates 37 stem cell and DNA medical treatment facilities in China, with additional presence in Indonesia and Cambodia.
Kelvin Chen, CEO of EUDA, expressed optimism about combining EUDA's holistic wellness products with Guangdong Cell Biotech’s established facilities to diversify healthcare offerings and revenue streams. Wang Taihua, Founder and Chairman of Guangdong Cell Biotech, highlighted the massive market for stem cell treatment in China and across Asia.
It is important to note that these discussions are in early stages, and no letter of intent or legally binding agreement has been entered into at this time. There is no guarantee that the parties will form a joint venture or enter into a definitive written agreement.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.